To amend title XXVII of the Public Health Service Act to establish civil liability for health insurance issuers with high levels of claims denials.
Summary
HR8442 (Patient Refunds for Bad Denials Act) is an early-stage bill with one sponsor and one cosponsor, referred to committee on April 22, 2026. It proposes civil penalties for health insurers with claims denial rates at or above 25%, but faces a long legislative path. Major health insurers ($HUM, $CI, $CVS) have rallied 9-38% over 30 days, and this bill presents no immediate stock-moving catalyst given its procedural stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8442 is a procedural early-stage bill with no near-term market impact.
- 2.The bill authorizes no spending—it creates a penalty framework with no funding mechanism.
- 3.Real market data shows health insurers rallying significantly post-introduction, indicating the market is not pricing in this risk.
- 4.Legislative path requires passage through both chambers and presidential signature—unlikely in current form given limited support.
Market Implications
No immediate market implications given the bill's procedural stage. The 9-38% rally in major health insurers over the past 30 days reflects sector fundamentals, not legislative overhang. $HUM at $238.85, $CI at $291.50, and $CVS at $83.11 all trade near their recent highs, with no selling pressure observed around the April 22 introduction date. Investors should monitor committee scheduling for any markup activity, which would be the first meaningful signal of legislative momentum.
Full Analysis
HR8442 was introduced on April 22, 2026 by Rep. Craig (D-MN) and referred to the House Committee on Energy and Commerce. The bill, with only one cosponsor and no further action history, is at the earliest legislative stage. It proposes a civil monetary penalty framework for health insurance issuers whose claims denial percentage reaches 25% or greater, with enforcement via HHS audits. However, this bill does not authorize or appropriate any funding—it creates a regulatory penalty structure. Actual market impact requires the bill to advance through subcommittee markup, full committee, House floor, Senate, and presidential action—a multi-year process with high attrition probability. Real market data shows $HUM up 37.75% over 30 days, $CI up 9.28%, and $CVS up 15.72%. These rallies are driven by factors unrelated to this bill (e.g., earnings, broader sector rotation), not legislative risk. $HUM's close on the bill's introduction date was $217.40, and it rose 9.9% over the following week to $238.85—directly contradicting any negative market reaction to the news.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
MERCK SHARP & DOHME LLC: $2.4B Department of Health and Human Services Contract Vehicle
PA DEPARTMENT OF HUMAN SERVICES: $1.0B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
HUMAN SERVICES, NEW JERSEY DEPARTMENT OF: $16.9B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
DEPARTMENT OF SOCIAL SERVICES MISSO: $15.1B Department of Health and Human Services Grant
MINNESOTA DEPARTMENT OF HUMAN SERVICES: $14.1B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →